Evidence map›Paper›PMID 29467463›Full record

ArticleNature communications2018

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.

Rajani Ravi, Kimberly A Noonan, Vui Pham, Rishi Bedi, Alex Zhavoronkov, Ivan V Ozerov, Eugene Makarev, Artem V Artemov, Piotr T Wysocki, Ranee Mehra and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 206 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 1 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 1 synthesis or guideline pooled it, 324 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020
    Trial
  4. Review
  5. Biomedicines · 2026
    Article
  6. Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Rajani RaviDepartment of Otolaryngology-Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Kimberly A NoonanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Vui PhamDepartment of Otolaryngology-Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Rishi BediDepartment of Computer Science, Stanford University, Palo Alto, CA, 94305, USA.
Alex ZhavoronkovInsilico Medicine, Inc., Emerging Technology Centers, Johns Hopkins University at Eastern, B301, 1101 33rd Street, Baltimore, MD, 21218, USA.
Ivan V OzerovInsilico Medicine, Inc., Emerging Technology Centers, Johns Hopkins University at Eastern, B301, 1101 33rd Street, Baltimore, MD, 21218, USA.
Eugene MakarevInsilico Medicine, Inc., Emerging Technology Centers, Johns Hopkins University at Eastern, B301, 1101 33rd Street, Baltimore, MD, 21218, USA.
Artem V ArtemovInsilico Medicine, Inc., Emerging Technology Centers, Johns Hopkins University at Eastern, B301, 1101 33rd Street, Baltimore, MD, 21218, USA.
Piotr T WysockiDepartment of Otolaryngology-Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Ranee MehraDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Sridhar NimmagaddaDepartment of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0002-6413-7191
Luigi MarchionniCenter for Computational Genomics, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
David SidranskyDepartment of Otolaryngology-Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Ivan M BorrelloSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Evgeny IzumchenkoDepartment of Otolaryngology-Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Atul BediDepartment of Otolaryngology-Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA. abedi1@jhmi.edu.
Johns Hopkins University · USPalo Alto University · US

Funding

TUMOR SUPPRESOR GENE PROMOTER HYPERMETHYLATION FOR DETECTION OF HEAD AND NECKP50DE019032 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 2007 to 2016
$27.1M
Bifunctional Immunostimulatory Antibodies for Treatment of Breast CancerR01CA184199 · NCI · JOHNS HOPKINS UNIVERSITY · PI BEDI, ATUL, RAVI, RAJANI · 2014 to 2018
$1.7M
NCI NIH HHS R01 CA184199NIDCR NIH HHS P50 DE019032
6 · The paper itself

Abstract

A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8

Indexed as

ImmunotherapyAnimalsAntibodiesB7-H1 AntigenBreast NeoplasmsCohort StudiesCTLA-4 AntigenFemaleForkhead Transcription FactorsHumansLymphocytes, Tumor-InfiltratingMelanomaMiceMice, Inbred NODReceptors, Transforming Growth Factor betaTh17 CellsAntibodiesB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanForkhead Transcription FactorsFOXP3 protein, humanReceptors, Transforming Growth Factor betaTransforming Growth Factor beta

Identifiers

PMID29467463
PMCPMC5821872
OpenAlexW2789421415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.